Honliv Healthcare Management Group Co Ltd

Honliv Healthcare has a market capitalization of 936 million CNY and a price-to-earnings ratio of 30.05, indicating a relatively high valuation compared to its earnings. The company's price-to-book ratio of 1.63 suggests that the market values the company at a premium to its book value. The debt-to-equity ratio of 0.31 indicates a conservative capital structure, with total liabilities of 400.998 million CNY and total equity of 573.005 million CNY. However, the company's liquidity is assessed as medium, with a current ratio of 1.01, suggesting limited short-term liquidity cushion. In terms of profitability, Honliv's return on equity (ROE) of 5.44% and return on assets (ROA) of 3.2% are below the typical thresholds for high-performing healthcare firms. The company's operating income of 50.421 million CNY and net income of 31.151 million CNY reflect modest profitability, with a gross profit margin of 16.5%. These figures suggest that the company is not outperforming the industry median in terms of efficiency and profitability. Honliv's revenue of 768.725 million CNY is derived from its operations in the healthcare sector, with no disclosed segment or geographic breakdown. The lack of segmental data limits the ability to assess revenue concentration or diversification. The company's exposure to geographic markets is not specified, but its operations are likely concentrated in China given its listing on the Hong Kong Stock Exchange. The company's growth trajectory is not clearly defined, as there are no specific numeric deltas provided for the current or next fiscal year. However, the company's operating cash flow of 83.344 million CNY and free cash flow of 53.842 million CNY indicate some capacity for reinvestment or debt reduction. The capital expenditure of -52.158 million CNY suggests that the company is not currently investing heavily in new assets. The risk assessment for Honliv highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could pose challenges in maintaining liquidity. The dilution risk is low, with no significant dilution potential identified in the basic shares outstanding. The company's conservative debt levels and stable cash flows may mitigate some of these risks. Recent events and filings for Honliv are not detailed in the provided data, so no specific recent developments can be cited. The company's financial performance and risk profile suggest a stable but not particularly dynamic business model, with limited exposure to high-growth opportunities or significant risks.